Tests magnesium sulfate injected into brain arteries after stroke clot removal
Tests safety of magnesium sulfate given into brain arteries in adults with acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke
Key facts
- Where
- Houston, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 95 years old?
Source: NCT06956521, who can take part
Where in United States
- Baylor St. Luke's Medical CenterHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Baylor College of Medicine
- Trial code
- NCT06956521
- Record updated
- 1 October 2026
- Original description
The goal of this Phase I unblinded, dose-escalation trial is to evaluate the safety and tolerability of intra-arterial magnesium sulfate injection after mechanical thrombectomy in patients experiencing acute ischemic stroke. This trial is one of the first trials to look at IA administration of magnesium sulfate into at risk brain tissue in a selective and localized fashion.Read full original descriptionShow less
Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke
The goal of this Phase I unblinded, dose-escalation trial is to evaluate the safety and tolerability of intra-arterial magnesium sulfate injection after mechanical thrombectomy in patients experiencing acute ischemic stroke. This trial is one of the first trials to look at IA administration of magnesium sulfate into at risk brain tissue in a selective and localized fashion.
Inclusion: Patient with acute cerebral ischemia due to ICA or MCA occlusion; Major neurologic deficits: 6≤NIHSS≤20,; Premorbid mRS 0 or 1, or 2; Patient's clinical attending physician plans MT procedure as part of routine clinical care,; undergo MT with a TICI 2a or better recanalization,; Signed informed consent.
Exclusion: mRS>2 caused by a history of prior stroke,; Unsuitable for this clinical study assessed by researcher. Subjects will not be excluded if they received IV t-PA as standard of care; subjects on therapeutic anticoagulation, as it is a relative contraindication to MT, and could be a confounding variable predisposing to intracranial hemorrhage including coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia <80000/mm3; Second or third-degree heart block without a pacemaker in place,; patients taking digoxin or other cardiac glycoside; Patient already enrolled in another experimental treatment trial. Exclusion criteria 1-3 are all contraindications to magnesium therapy,; Severe hepatic dysfunction, severe renal dysfunction (<30 mL/min), increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; Positive pregnancy test; those undergoing MT with a TICI <2a revascularization; tandem occlusion of the cervical common or internal carotid artery; and; Technical inability to navigate micro-catheter to target clot,; patient is on neuromuscular blocking agents including depolarizing (succinylcholine) and nondepolarizing subtypes (rocuronium, vecuronium, etc); patient is taking any form of CNS depressant including barbiturates, narcotics, outside the setting of anesthesia or ICU sedation.